UK Biobank Analyses and Preclinical Data on Hepatic Plasminogen Lowering Presented at the 2025 European Hematology Association (EHA) Congress

15 Jun, 2025 UK Biobank Analyses and Preclinical Data on Hepatic Plasminogen Lowering Presented at the 2025 European Hematology Association (EHA) Congress

Human genetics and proteomics data from UK Biobank as well as data from preclinical models relevant to ALN-6400—an investigational RNAi therapeutic targeting plasminogen for bleeding disorders—were presented at the 2025 European Hematology Association (EHA) Congress, June 12-15, Milan, Italy.

Ivanciu, et al. “Hepatic plasminogen lowering with RNA interference for the treatment of bleeding disorders is unlikely to pose thrombotic risk based on UK Biobank analyses and mouse models of provoked thrombosis.”